Sunnie Kim, MD, of University of Colorado Medicine, provides an overview of the recent FDA approval of tislelizumab for the treatment of advanced or metastatic
The US Food and Drug Administration (FDA) has approved tislelizumab Fewer patients in the tislelizumab arm experienced grade 3 or greater treatment-emergent adverse events compared with the
Tislelizumab was approved for medical use in China in December 2024, in U.S. Food and Drug Administration (FDA). Archived from
Data from the phase 3 RATIONALE 302 trial (NCT ) supported the FDA approval of tislelizumab-jsgr as a treatment for those with
(FDA) has approved TEVIMBRA (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic
FDA approval sought for frontline Tevimbra (tislelizumab) in locally advanced or metastatic esophageal squamous cell carcinoma – BeiGene.
BeiGene, Ltd, received approval from the US FDA for TEVIMBRA (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or
Currently approved for use in China, tislelizumab is under review by both the FDA and the European Medicines Agency (EMA) for advanced or
The FDA has approved tislelizumab-jsgr (TEVIMBRA) for single-agent use in adult patients with unresectable or metastatic ESCC following
Comments
What the hell would the FDA have to do with it? This is a piece of machinery. They would have NO say about it whatsoever.
Good story - would like to see more!
Do you realize the world doesn't end at USA borders?